Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

167391

registered interest
date	02/12/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Tuberculosis: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what support his Department provides to research into finding new vaccines for antibiotic resistant strains of TB; and if he will make a statement.
tabling member constituency	Brighton, Kemptown
tabling member printed	Simon Kirby
uin	216738
answer	answer is ministerial correction date of answer 09/12/2014 answer text <p>The Department for Business, Innovation and Skills supports research into TB through the UK Research Councils who support a broad portfolio of research addressing different aspects of the disease. This includes research on vaccines and treatments for antibiotic resistant strains of TB.</p><p> </p><p>The Medical Research Council (MRC) currently supports five projects directly relating to antibiotic resistant strains of TB with a total value of £5.7m. These include studies which aim to identify novel targets for antibacterial drug discovery, the development of new TB vaccines and antibiotics, clinical trials with a focus on translational and implementation research relevant to developing countries, and health services and health systems research.</p><p> </p><p>The MRC is also leading an anti-microbial resistance (AMR) funders’ forum to coordinate activities in this area and an initiative involving all of the UK Research Councils on which aims to tackle resistance and try to develop treatments and diagnostic tools. In addition the MRC also supports a broader portfolio of research into TB likely to improve our understanding and inform future research into antibiotic resistant strains.</p><p> </p><p>The Biotechnology and Biological Sciences Research Council (BBSRC) are funding research into new treatments for antibiotic resistant strains of TB in addition to research on vaccine development, which while not specifically addressing antibiotic resistant strains is likely to improve our understanding and inform future research.</p><p> </p><p>An Economic and Social Research Council (ESRC) funded study aims identify barriers to tuberculosis diagnosis and treatment uptake while an EPSRC fellowship is looking at the transmission dynamics of TB.</p><p> </p><p>Researchers are also using the Diamond Light Source, to identify ways of disabling the enzyme that protects the TB bacteria and to understand the structure of the protein that enables the TB bacteria to survive in the human body. It is hoped that this work will make existing treatments easier and more effective and to help design new drugs. The Diamond Light Source is the UK’s national synchrotron, funded by the Science and Technology Facilities Council (STFC).</p><p> </p><p>The UK is also a member of the European and Developing Countries Clinical Trials Partnership (EDCTP) which aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis, malaria and other neglected diseases. In December 2014 the second phase of the partnership, EDCTP2 was launched aiming to contribute over 1billion euros over the next 10 years. Further information can be found at: <a href="http://www.edctp.org/" target="_blank">http://www.edctp.org/</a></p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 216741 question first answered 09/12/2014 11:14:42 answering member 4020 label Biography information for George Freeman
tabling member	3929 label Biography information for Simon Kirby

167392

registered interest
date	02/12/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Ebola
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what support his Department provides to research into finding a cure for Ebola; and if he will make a statement.
tabling member constituency	Brighton, Kemptown
tabling member printed	Simon Kirby
uin	216739
answer	answer is ministerial correction date of answer 09/12/2014 answer text <p>The Department for Business, Innovation and Skills supports research into Ebola through the UK Research Councils who support a number of research projects addressing different aspects of the disease. This includes work on vaccines, treatments and interventions, and finding a cure.</p><p> </p><p>Current Medical Research Council (MRC) funded research includes a £2.8m grant funding jointly by the MRC, the Wellcome Trust and DFID to allow a team led by the University of Oxford to test the safety of a candidate vaccine alongside similar trials in the US.</p><p> </p><p>The MRC Centre for Outbreak Analysis and Modelling, at Imperial College London, is an official WHO Collaborating Centre for Infectious Disease Modelling. Researchers there have been providing advice to the WHO regarding the current Ebola outbreak in West Africa and contributed to a study reviewing data since the beginning of the outbreak in December 2013 to determine the scale of the epidemic, better understand the spread of the disease, and explore what it will take to reverse the trend of infections.</p><p> </p><p>The Economic and Social Research Council (ESRC) is supporting one £3.6m study which aims to improve our understanding of the cultural and political dimension to inform interventions. In addition researchers funded by the Science and Technology Facilities Council (STFC) are using the Diamond Light Source to investigate emerging viruses are making an Ebola protein for therapeutic antibodies. The Diamond Light Source is the UK’s national synchrotron and is also funded by STFC.</p><p> </p><p>The UK is also a member of the European and Developing Countries Clinical Trials Partnership (EDCTP) which aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis, malaria and other neglected diseases, including Ebola. In December 2014 the second phase of the partnership, EDCTP2 was launched aiming to contribute over 1billion euros over the next 10 years. Further information can be found at: <a href="http://www.edctp.org/" target="_blank">http://www.edctp.org/</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 216740 question first answered 09/12/2014 14:19:58 answering member 4020 label Biography information for George Freeman
tabling member	3929 label Biography information for Simon Kirby

167393

registered interest
date	02/12/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Ebola: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what support his Department provides to research into finding a vaccine for Ebola; and if he will make a statement.
tabling member constituency	Brighton, Kemptown
tabling member printed	Simon Kirby
uin	216740
answer	answer is ministerial correction date of answer 09/12/2014 answer text <p>The Department for Business, Innovation and Skills supports research into Ebola through the UK Research Councils who support a number of research projects addressing different aspects of the disease. This includes work on vaccines, treatments and interventions, and finding a cure.</p><p> </p><p>Current Medical Research Council (MRC) funded research includes a £2.8m grant funding jointly by the MRC, the Wellcome Trust and DFID to allow a team led by the University of Oxford to test the safety of a candidate vaccine alongside similar trials in the US.</p><p> </p><p>The MRC Centre for Outbreak Analysis and Modelling, at Imperial College London, is an official WHO Collaborating Centre for Infectious Disease Modelling. Researchers there have been providing advice to the WHO regarding the current Ebola outbreak in West Africa and contributed to a study reviewing data since the beginning of the outbreak in December 2013 to determine the scale of the epidemic, better understand the spread of the disease, and explore what it will take to reverse the trend of infections.</p><p> </p><p>The Economic and Social Research Council (ESRC) is supporting one £3.6m study which aims to improve our understanding of the cultural and political dimension to inform interventions. In addition researchers funded by the Science and Technology Facilities Council (STFC) are using the Diamond Light Source to investigate emerging viruses are making an Ebola protein for therapeutic antibodies. The Diamond Light Source is the UK’s national synchrotron and is also funded by STFC.</p><p> </p><p>The UK is also a member of the European and Developing Countries Clinical Trials Partnership (EDCTP) which aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis, malaria and other neglected diseases, including Ebola. In December 2014 the second phase of the partnership, EDCTP2 was launched aiming to contribute over 1billion euros over the next 10 years. Further information can be found at: <a href="http://www.edctp.org/" target="_blank">http://www.edctp.org/</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 216739 question first answered 09/12/2014 14:19:58 answering member 4020 label Biography information for George Freeman
tabling member	3929 label Biography information for Simon Kirby

167394

registered interest
date	02/12/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Tuberculosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what support his Department provides to research into finding new treatments for antibiotic resistant strains of TB; and if he will make a statement.
tabling member constituency	Brighton, Kemptown
tabling member printed	Simon Kirby
uin	216741
answer	answer is ministerial correction date of answer 09/12/2014 answer text <p>The Department for Business, Innovation and Skills supports research into TB through the UK Research Councils who support a broad portfolio of research addressing different aspects of the disease. This includes research on vaccines and treatments for antibiotic resistant strains of TB.</p><p> </p><p>The Medical Research Council (MRC) currently supports five projects directly relating to antibiotic resistant strains of TB with a total value of £5.7m. These include studies which aim to identify novel targets for antibacterial drug discovery, the development of new TB vaccines and antibiotics, clinical trials with a focus on translational and implementation research relevant to developing countries, and health services and health systems research.</p><p> </p><p>The MRC is also leading an anti-microbial resistance (AMR) funders’ forum to coordinate activities in this area and an initiative involving all of the UK Research Councils on which aims to tackle resistance and try to develop treatments and diagnostic tools. In addition the MRC also supports a broader portfolio of research into TB likely to improve our understanding and inform future research into antibiotic resistant strains.</p><p> </p><p>The Biotechnology and Biological Sciences Research Council (BBSRC) are funding research into new treatments for antibiotic resistant strains of TB in addition to research on vaccine development, which while not specifically addressing antibiotic resistant strains is likely to improve our understanding and inform future research.</p><p> </p><p>An Economic and Social Research Council (ESRC) funded study aims identify barriers to tuberculosis diagnosis and treatment uptake while an EPSRC fellowship is looking at the transmission dynamics of TB.</p><p> </p><p>Researchers are also using the Diamond Light Source, to identify ways of disabling the enzyme that protects the TB bacteria and to understand the structure of the protein that enables the TB bacteria to survive in the human body. It is hoped that this work will make existing treatments easier and more effective and to help design new drugs. The Diamond Light Source is the UK’s national synchrotron, funded by the Science and Technology Facilities Council (STFC).</p><p> </p><p>The UK is also a member of the European and Developing Countries Clinical Trials Partnership (EDCTP) which aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis, malaria and other neglected diseases. In December 2014 the second phase of the partnership, EDCTP2 was launched aiming to contribute over 1billion euros over the next 10 years. Further information can be found at: <a href="http://www.edctp.org/" target="_blank">http://www.edctp.org/</a></p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 216738 question first answered 09/12/2014 11:14:43 answering member 4020 label Biography information for George Freeman
tabling member	3929 label Biography information for Simon Kirby

167395

registered interest
date	02/12/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	HIV Infection: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what support his Department provides to research into finding a vaccine for HIV; and if he will make a statement.
tabling member constituency	Brighton, Kemptown
tabling member printed	Simon Kirby
uin	216742
answer	answer is ministerial correction date of answer 09/12/2014 answer text <p>The Department for Business, Innovation and Skills (BIS) supports research into HIV/AIDS through the UK Research Councils who support a broad portfolio of research addressing different aspects of the disease. This includes research on vaccines and interventions.</p><p> </p><p> </p><p> </p><p>Research supported by the Research Councils includes Medical Research Council (MRC) funded studies which aim to understand the mechanisms of HIV infection through to novel strategies for preventing and controlling infections through research on human behaviour and lifestyle. Research supported by the Economic and Social Research Council (ESRC) includes an evaluation of the impact of health care schemes in Rwanda providing basic preventive and curative health care services and HIV/AIDS treatment in addition to Engineering and Physical Sciences Research Council (EPSRC) funded research on drug delivery and vaccine delivery technology involving nanomedicines.</p><p> </p><p> </p><p> </p><p>Researchers are also using the Diamond Light Source to advance the understanding of how HIV and other retroviruses infect human cells and replicate to inform the development of better treatments. The Diamond Light Source is the UK’s national synchrotron, funded by the Science and Technology Facilities Council (STFC).</p><p> </p><p> </p><p> </p><p>The UK is also a member of the European and Developing Countries Clinical Trials Partnership (EDCTP) which aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis, malaria and other neglected diseases. In December 2014 the second phase of the partnership, EDCTP2 was launched aiming to contribute over 1billion euros over the next 10 years. Further information can be found at: <a href="http://www.edctp.org/" target="_blank">http://www.edctp.org/</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 216743 question first answered 09/12/2014 13:12:54 answering member 4020 label Biography information for George Freeman
tabling member	3929 label Biography information for Simon Kirby

167396

registered interest
date	02/12/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	HIV Infection
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what support his Department provides to research into finding a cure for HIV/AIDS; and if he will make a statement.
tabling member constituency	Brighton, Kemptown
tabling member printed	Simon Kirby
uin	216743
answer	answer is ministerial correction date of answer 09/12/2014 answer text <p>The Department for Business, Innovation and Skills (BIS) supports research into HIV/AIDS through the UK Research Councils who support a broad portfolio of research addressing different aspects of the disease. This includes research on vaccines and interventions.</p><p> </p><p> </p><p> </p><p>Research supported by the Research Councils includes Medical Research Council (MRC) funded studies which aim to understand the mechanisms of HIV infection through to novel strategies for preventing and controlling infections through research on human behaviour and lifestyle. Research supported by the Economic and Social Research Council (ESRC) includes an evaluation of the impact of health care schemes in Rwanda providing basic preventive and curative health care services and HIV/AIDS treatment in addition to Engineering and Physical Sciences Research Council (EPSRC) funded research on drug delivery and vaccine delivery technology involving nanomedicines.</p><p> </p><p> </p><p> </p><p>Researchers are also using the Diamond Light Source to advance the understanding of how HIV and other retroviruses infect human cells and replicate to inform the development of better treatments. The Diamond Light Source is the UK’s national synchrotron, funded by the Science and Technology Facilities Council (STFC).</p><p> </p><p> </p><p> </p><p>The UK is also a member of the European and Developing Countries Clinical Trials Partnership (EDCTP) which aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis, malaria and other neglected diseases. In December 2014 the second phase of the partnership, EDCTP2 was launched aiming to contribute over 1billion euros over the next 10 years. Further information can be found at: <a href="http://www.edctp.org/" target="_blank">http://www.edctp.org/</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 216742 question first answered 09/12/2014 13:12:54 answering member 4020 label Biography information for George Freeman
tabling member	3929 label Biography information for Simon Kirby

167496

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the contribution by the Parliamentary Under Secretary of State for Health on the Off-patent Drugs Bill of 7 November 2014, columns 1114-1118, what discussions he has had with hospitals and GPs on changing clinical pathways to reflect the latest evidence to improve the uptake of effective off-patent drugs; what steps he has taken to set up a round-table discussion of these issues with NHS England and the National Institute for Health and Care Excellence (NICE); when this discussion will take place; and what steps he has taken to accelerate the uptake of (a) off-patent drugs and (b) innovative medicines through NICE guidance.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	216943
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>We have had no such discussions with hospital doctors and general practitioners. Clinicians can already prescribe off-patent drugs and these are widely used in the National Health Service but we are in the process of setting up a round-table discussion with key stakeholders, and are discussing suitable dates with them. Current prescribing arrangements allow clinicians to prescribe such drugs off-label and off-license when it best meets their patients individual clinical needs.</p><p> </p><p>The majority of significant new drugs are referred to the National Institute for Health and Care Excellence (NICE) technology appraisal work programme. NHS commissioners are required to fund drugs and treatments recommended by NICE technology appraisal guidance. Other NICE guidance, including clinical guidelines, may address the use of off-patent drugs for treating particular conditions and we expect clinicians and commissioners to take account of this guidance.</p><p> </p><p> </p><p> </p><p>The Government has recently launched an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology to consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/12/2014 13:09:58 answering member 4020 label Biography information for George Freeman
tabling member	4125 label Biography information for Catherine McKinnell

167505

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Nalmefene
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what guidance his Department issues on whether local authorities or clinical commissioning groups should fund the cost of the drug Nalmefene.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	216875
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) published technology appraisal guidance on 26 November which recommends nalmefene (Selincro) as a possible treatment for people with alcohol dependence, subject to certain criteria.</p><p> </p><p> </p><p> </p><p>NHS commissioners and local authorities, with respect to their public health functions, are legally required to make funding available for treatments recommended by NICE technology appraisal guidance, within three months of NICE’s final guidance.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/12/2014 13:14:18 answering member 4020 label Biography information for George Freeman
tabling member	4036 label Biography information for Luciana Berger

167507

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure that the treatment for pancreatic cancer listed by the Cancer Drugs Fund will continue to be made available to patients on the NHS.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	216794
answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>NHS England’s Cancer Drugs Fund panel plans to assess, on the basis of the latest evidence, whether certain drugs, including Abraxane (albumin bound paclitaxel) for advanced pancreatic cancer, should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.<br> <br></p><p> </p><p>We are committed to maintaining the Cancer Drugs Fund until the end of March 2016. We will carefully consider with NHS England what arrangements should be put in place for the long term.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 08/12/2014 15:04:29 answering member 4020 label Biography information for George Freeman
tabling member	1604 label Biography information for Mr Virendra Sharma

167513

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sleeping Pills
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent representations he has received on the prescription of zolpidem.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	216755
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>In the 6 month period, June 2014 to November 2014, the Department received no written representations concerning the prescribing of zolpidem (Stilnoct).</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/12/2014 12:50:25 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon